Publication Information

{'id': 'https://openalex.org/W2607780130', 'doi': 'https://doi.org/10.21037/cco.2017.04.01', 'title': 'Immunotherapy of patients with metastatic melanoma', 'display_name': 'Immunotherapy of patients with metastatic melanoma', 'publication_year': 2017, 'publication_date': '2017-04-01', 'ids': {'openalex': 'https://openalex.org/W2607780130', 'doi': 'https://doi.org/10.21037/cco.2017.04.01', 'mag': '2607780130', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/28482673'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.21037/cco.2017.04.01', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764664221', 'display_name': 'Chinese Clinical Oncology', 'issn_l': '2304-3865', 'issn': ['2304-3865', '2304-3873'], 'is_oa': True, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310321814', 'host_organization_name': 'AME Publishing Company', 'host_organization_lineage': ['https://openalex.org/P4310321814'], 'host_organization_lineage_names': ['AME Publishing Company'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5020497561', 'display_name': 'Zhe Yu', 'orcid': 'https://orcid.org/0000-0002-4936-4871'}, 'institutions': [{'id': 'https://openalex.org/I191996457', 'display_name': 'Dalian Medical University', 'ror': 'https://ror.org/04c8eg608', 'country_code': 'CN', 'type': 'education', 'lineage': ['https://openalex.org/I191996457']}, {'id': 'https://openalex.org/I4210100868', 'display_name': 'Second Affiliated Hospital of Dalian Medical University', 'ror': 'https://ror.org/012f2cn18', 'country_code': 'CN', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210100868']}], 'countries': ['CN'], 'is_corresponding': False, 'raw_author_name': 'Zhe Yu', 'raw_affiliation_strings': ['Department of Medical Oncology, The Second Affiliated Hospital, Dalian Medical University, Dalian 116044, China'], 'affiliations': [{'raw_affiliation_string': 'Department of Medical Oncology, The Second Affiliated Hospital, Dalian Medical University, Dalian 116044, China', 'institution_ids': ['https://openalex.org/I191996457', 'https://openalex.org/I4210100868']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5018372804', 'display_name': 'Lu Si', 'orcid': 'https://orcid.org/0000-0002-2123-9761'}, 'institutions': [{'id': 'https://openalex.org/I20231570', 'display_name': 'Peking University', 'ror': 'https://ror.org/02v51f717', 'country_code': 'CN', 'type': 'education', 'lineage': ['https://openalex.org/I20231570']}, {'id': 'https://openalex.org/I4210093964', 'display_name': 'Peking University Cancer Hospital', 'ror': 'https://ror.org/00nyxxr91', 'country_code': 'CN', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210093964']}], 'countries': ['CN'], 'is_corresponding': True, 'raw_author_name': 'Lu Si', 'raw_affiliation_strings': ['The Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China'], 'affiliations': [{'raw_affiliation_string': 'The Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China', 'institution_ids': ['https://openalex.org/I20231570', 'https://openalex.org/I4210093964']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 4, 'corresponding_author_ids': ['https://openalex.org/A5018372804'], 'corresponding_institution_ids': ['https://openalex.org/I20231570', 'https://openalex.org/I4210093964'], 'apc_list': None, 'apc_paid': None, 'fwci': 0.922, 'has_fulltext': False, 'cited_by_count': 13, 'citation_normalized_percentile': {'value': 0.779733, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 87, 'max': 88}, 'biblio': {'volume': '6', 'issue': '2', 'first_page': '20', 'last_page': '20'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9996, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9996, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10580', 'display_name': 'Immunotherapy and Immune Responses', 'score': 0.9987, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T11491', 'display_name': 'CAR-T cell therapy research', 'score': 0.989, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.9515317}, {'id': 'https://openalex.org/C2781433595', 'wikidata': 'https://www.wikidata.org/wiki/Q2459042', 'display_name': 'Ipilimumab', 'level': 4, 'score': 0.94278264}, {'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.90110326}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.82059205}, {'id': 'https://openalex.org/C2777658100', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Melanoma', 'level': 2, 'score': 0.75979674}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.59036505}, {'id': 'https://openalex.org/C2994587330', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Metastatic melanoma', 'level': 3, 'score': 0.5782912}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.5411221}, {'id': 'https://openalex.org/C2780030458', 'wikidata': 'https://www.wikidata.org/wiki/Q7041828', 'display_name': 'Nivolumab', 'level': 4, 'score': 0.49397427}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.4426692}, {'id': 'https://openalex.org/C61511704', 'wikidata': 'https://www.wikidata.org/wiki/Q1671857', 'display_name': 'Incidence (geometry)', 'level': 2, 'score': 0.4369756}, {'id': 'https://openalex.org/C535046627', 'wikidata': 'https://www.wikidata.org/wiki/Q30612', 'display_name': 'Clinical trial', 'level': 2, 'score': 0.4196331}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.16260988}, {'id': 'https://openalex.org/C121332964', 'wikidata': 'https://www.wikidata.org/wiki/Q413', 'display_name': 'Physics', 'level': 0, 'score': 0.0}, {'id': 'https://openalex.org/C120665830', 'wikidata': 'https://www.wikidata.org/wiki/Q14620', 'display_name': 'Optics', 'level': 1, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D007167', 'descriptor_name': 'Immunotherapy', 'qualifier_ui': 'Q000379', 'qualifier_name': 'methods', 'is_major_topic': True}, {'descriptor_ui': 'D008545', 'descriptor_name': 'Melanoma', 'qualifier_ui': 'Q000628', 'qualifier_name': 'therapy', 'is_major_topic': True}, {'descriptor_ui': 'D012878', 'descriptor_name': 'Skin Neoplasms', 'qualifier_ui': 'Q000628', 'qualifier_name': 'therapy', 'is_major_topic': True}, {'descriptor_ui': 'D000911', 'descriptor_name': 'Antibodies, Monoclonal', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000911', 'descriptor_name': 'Antibodies, Monoclonal', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D060908', 'descriptor_name': 'CTLA-4 Antigen', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': False}, {'descriptor_ui': 'D060908', 'descriptor_name': 'CTLA-4 Antigen', 'qualifier_ui': 'Q000276', 'qualifier_name': 'immunology', 'is_major_topic': False}, {'descriptor_ui': 'D060908', 'descriptor_name': 'CTLA-4 Antigen', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D007167', 'descriptor_name': 'Immunotherapy', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008545', 'descriptor_name': 'Melanoma', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011379', 'descriptor_name': 'Prognosis', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D061026', 'descriptor_name': 'Programmed Cell Death 1 Receptor', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D012878', 'descriptor_name': 'Skin Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.21037/cco.2017.04.01', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764664221', 'display_name': 'Chinese Clinical Oncology', 'issn_l': '2304-3865', 'issn': ['2304-3865', '2304-3873'], 'is_oa': True, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310321814', 'host_organization_name': 'AME Publishing Company', 'host_organization_lineage': ['https://openalex.org/P4310321814'], 'host_organization_lineage_names': ['AME Publishing Company'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/28482673', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.64}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4362552730', 'https://openalex.org/W4362552617', 'https://openalex.org/W4313890856', 'https://openalex.org/W4236421112', 'https://openalex.org/W3043703771', 'https://openalex.org/W2973740076', 'https://openalex.org/W2963333658', 'https://openalex.org/W2888298425', 'https://openalex.org/W2766929851', 'https://openalex.org/W2366936450'], 'abstract_inverted_index': {'Abstract:': [0], 'Malignant': [1], 'melanoma': [2], '(MM)': [3], 'is': [4, 16], 'the': [5, 14, 19, 33, 45, 57, 102], 'primary': [6], 'cause': [7], 'of': [8, 35, 48, 96, 104, 120], 'skin': [9], 'cancer': [10], 'related': [11], 'death': [12], 'and': [13, 52, 59, 124], 'incidence': [15], 'increasing': [17], 'in': [18, 30, 70, 127], 'past': [20], 'years.': [21], 'Advanced': [22], 'MM': [23, 105], 'still': [24], 'has': [25, 37], 'a': [26], 'poor': [27, 40], 'prognosis,': [28], 'but': [29], 'recent': [31], 'years,': [32], 'development': [34], 'immunotherapy': [36, 77, 88, 97], 'changed': [38], 'its': [39], 'prognosis.': [41], 'Immune': [42], 'checkpoints': [43], 'show': [44], 'revolutionary': [46], 'treatment': [47, 103], 'metastatic': [49], 'melanoma.': [50, 74, 130], 'Ipilimumab': [51], 'pembrolizumab,': [53], 'monoclonal': [54], 'antibodies': [55], 'against': [56], 'CTLA-4': [58], 'PD-1': [60], 'respectively,': [61], 'have': [62], 'been': [63], 'shown': [64], 'to': [65, 79, 82, 112], 'prolong': [66], 'overall': [67], 'survival': [68], '(OS)': [69], 'patients': [71, 128], 'with': [72, 129], 'advanced': [73], 'The': [75, 94], 'combination': [76, 95, 119], 'seems': [78], 'be': [80], 'superior': [81], 'monotherapy.': [83], 'In': [84], 'this': [85], 'review,': [86], 'recently': [87], 'clinical': [89], 'trial': [90], 'results': [91], 'are': [92, 110], 'presented.': [93], 'provides': [98], 'new': [99], 'options': [100], 'for': [101], 'patients.': [106], 'However,': [107], 'further': [108], 'studies': [109], 'necessary': [111], 'answer': [113], 'such': [114], 'question': [115], 'as': [116], 'optimal': [117], 'treatment,': [118], 'immunotherapies,': [121], 'crowd': [122], 'selection': [123], 'risk': [125], 'balance': [126]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2607780130', 'counts_by_year': [{'year': 2023, 'cited_by_count': 3}, {'year': 2022, 'cited_by_count': 1}, {'year': 2021, 'cited_by_count': 2}, {'year': 2020, 'cited_by_count': 2}, {'year': 2019, 'cited_by_count': 3}, {'year': 2018, 'cited_by_count': 2}], 'updated_date': '2024-12-14T19:22:42.571855', 'created_date': '2017-05-05'}